Jack Bendheim Sells 6,693 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 6,693 shares of Phibro Animal Health stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $40.09, for a total transaction of $268,322.37. Following the transaction, the chief executive officer owned 31,980 shares in the company, valued at approximately $1,282,078.20. The trade was a 17.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total transaction of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.

Phibro Animal Health Trading Down 1.4%

Shares of NASDAQ:PAHC opened at $41.31 on Wednesday. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $46.42. The firm has a fifty day moving average price of $39.79 and a 200 day moving average price of $38.04. The stock has a market capitalization of $1.67 billion, a PE ratio of 24.89, a P/E/G ratio of 1.19 and a beta of 0.80. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The company had revenue of $363.89 million during the quarter, compared to the consensus estimate of $345.44 million. Analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health News Summary

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.12 per share payable March 25, 2026 (record date March 4). Dividend supports shareholder returns and can attract income-minded investors. Phibro Animal Health Corporation Declares Quarterly Dividend
• Positive Sentiment: Zacks Research reiterated a Strong-Buy and nudged several forward-year and quarterly EPS estimates higher (FY2027/FY2028 upgrades and Q4/Q2 tweaks), signaling improved analyst sentiment about medium-term earnings power. 4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
• Positive Sentiment: Institutional buying earlier (new positions reported from Capricorn Fund Managers, Allspring Global, Squarepoint and others) indicates continued interest from funds and helps support the stock’s valuation multiple. MarketBeat PAHC Profile
• Neutral Sentiment: Industry coverage pieces name PAHC among medical/animal-health names to watch amid steady demand despite macro headwinds — a constructive backdrop but not an immediate catalyst. 4 Medical Product Stocks to Watch From a Challenging Industry
• Negative Sentiment: CEO Jack Bendheim has executed a sequence of insider sales in January (recent disclosed sales include ~6,693 shares at ~$40.09), which investors often interpret as a sign of insider cashing out and can pressure sentiment. Phibro Animal Health CEO Jack Bendheim Sells Shares
• Negative Sentiment: Mixed analyst tweaks include a small near-term cut (Zacks trimmed Q2 2026 EPS modestly), which could feed short-term selling or cautious guidance expectations despite longer-term upgrades. (See Zacks notes above.)

Wall Street Analysts Forecast Growth

PAHC has been the subject of several research analyst reports. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and a consensus price target of $31.40.

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in shares of Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares in the last quarter. Hughes Financial Services LLC bought a new position in shares of Phibro Animal Health in the third quarter worth about $40,000. iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health in the third quarter valued at approximately $61,000. Advisory Services Network LLC bought a new position in Phibro Animal Health in the 3rd quarter valued at $96,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after acquiring an additional 2,685 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.